Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of M281 in adults with generalized myasthenia gravis
2018-002247-28Phase 2Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nipocalimab in myasthenia gravis (MG) (5 arms), sponsored by Momenta Pharmaceuticals. Primary endpoint: Incidence of adverse events. Started Nov 2018; status: completed.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2018-002247-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002247-28.